SEC Form 4	
------------	--

[]

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

I	OMB Number:	3235-0287
	Estimated average but	den
l	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a)

Filed			xchange Act of y Act of 1940	1934	

(Last) (First) (Middle) 531 SOUTH SPRING STREET 3. Date of Earliest Transaction (Month/Day/Year) A below) below) EVP, Chief Marketing Officer (Street) BURLINGTON NC 27215 6. Individual or Joint/Group Filing (Check Applicable Line) (City) (State) (Zip) Rule 10b5-1(c) Transaction Indication Form filed by One Reporting Person Person Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.	1. Name and Address of Reporting Person [*] Summy Amy B.	2. Issuer Name and Ticker or Trading Symbol <u>LABORATORY CORP OF AMERICA</u> <u>HOLDINGS</u> [LH]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify										
(Street) BURLINGTON NC 27215 (City) (State) (Zip) Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.			below) below)										
Rule TOD5-T(C) Transaction indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		Line) X Form filed by One Reporting Person Form filed by More than One Reporting											
	Rule 1005-1(C) Transaction indication												

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)						5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(
Common Stock	02/02/2024		М		246	Α	(1)	3,880	D	
Common Stock	02/02/2024		F ⁽²⁾		80	D	\$221.54	3,800	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exerc Expiration Da (Month/Day/)	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Unit	(1)	02/02/2024		М			246	(3)	(3)	Common Stock	246	\$ <mark>0</mark>	6,850 ⁽⁴⁾	D	

Explanation of Responses:

1. Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.

2. Stock withholding to satisfy tax withholding obligations.

3. The Restricted Stock Units vested in three equal annual installments beginning on February 2, 2022 and are now fully vested.

4. This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 92 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc.

/s/ Sandra D. van der Vaart,

Attorney-in-Fact for Amy B.

<u>Summy</u>

** Signature of Reporting Person Date

02/06/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.